Last reviewed · How we verify
Acute myocardial infarction — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Tnkase | TENECTEPLASE | Roche | fibrin | 2000-01-01 | ||
| Activase | ALTEPLASE | Roche | Plasminogen | 1996-01-01 | ||
| Metalyse | Metalyse | AO GENERIUM | Plasminogen | |||
| Activase | Activase | Medical College of Wisconsin | Plasminogen |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Roche · 2 drugs in Acute myocardial infarction
- AO GENERIUM · 1 drug in Acute myocardial infarction
- Medical College of Wisconsin · 1 drug in Acute myocardial infarction
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Acute myocardial infarction:
- Acute myocardial infarction treatment updates — RSS
- Acute myocardial infarction treatment updates — Atom
- Acute myocardial infarction treatment updates — JSON
Cite this brief
Drug Landscape (2026). Acute myocardial infarction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-myocardial-infarction. Accessed 2026-06-10.
Related
- Acute myocardial infarction full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing